Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

Lancet. 1994 Nov 26;344(8935):1453-7. doi: 10.1016/s0140-6736(94)90286-0.


We investigated whether the occurrence of venous thrombosis in young women who use oral contraceptives might be explained by the factor V Leiden mutation, which leads to resistance to activated protein C and enhances susceptibility to thrombosis. We compared 155 consecutive premenopausal women, aged 15 to 49, who had developed deep venous thrombosis in the absence of other underlying diseases, with 169 population controls. The risk of thrombosis among users of oral contraceptives was increased 4-fold (relative risk 3.8 [95% CI 2.4-6.0]). The risk of thrombosis among carriers of the mutation compared with non-carriers was increased 8-fold (7.9 [3.2-19.4]). Compared with women who did not use oral contraceptives and were not carriers of the mutation, the risk of thrombosis among those with both risk factors was increased more than 30-fold (34.7 [7.8-154]). Recalculation of population incidences from these relative risks shows that the absolute risk of venous thrombosis in young women who use oral contraceptives is much larger when they carry the factor V Leiden mutation. When a young woman develops thrombosis, her factor V Leiden status should be considered in counselling about her future method of contraception.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Case-Control Studies
  • Contraceptives, Oral / adverse effects*
  • Factor V / genetics*
  • Female
  • Heterozygote*
  • Humans
  • Logistic Models
  • Middle Aged
  • Mutation*
  • Netherlands
  • Protein C / genetics
  • Protein C / pharmacology
  • Risk
  • Risk Factors
  • Thrombophlebitis / blood
  • Thrombophlebitis / etiology*
  • Thrombophlebitis / genetics


  • Contraceptives, Oral
  • Protein C
  • Factor V